Climb Bio Inc

Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug which is in phase 2 clinical trials for the treatment of primary membranous nephropathy and immune thrombocytopenia; and Phase 1b clinical trial indicated for the systemic lupus erythematosus. In addition, the company is developing CLYM116, a preclinical stage anti A Proliferation-inducing Ligand (APRIL) monoclonal antibody for the treatment of immunoglobin A nephropathy (IgAN) and other B-cell mediated diseases. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wellesley Hills, Massachusetts.

CLYM▲

5 Biotech Stocks That Delivered 100% To 300% Gains

Five biotech stocks highlighted in RTTNews reports have delivered gains ranging from 100% to over 300% since their respective publication dates. Climb Bio Inc. rose 310% to $12.90 from a published price of $3.14 on December 15, 2025, driven by pipeline progress and positive early clinical data for Budoprutug and CLYM116. Tectonic Therapeutic Inc. gained 121% to $37.93 from $17.15 on October 27, 2025, following positive Phase 1b results for TX45 and initiation of multiple clinical trials. UroGen Pharma Ltd. climbed 280% to $38.02 from $10.01 on April 25, 2025, after FDA approval of Zusduri and strong revenue growth. Eton Pharmaceuticals Inc. advanced 128% to $37.50 from $16.44 on December 11, 2025, supported by FDA approval of DESMODA and multiple commercial deals. Liquidia Corp. surged 249% to $78.93 from $22.59 on October 17, 2025, fueled by the launch and expanding adoption of Yutrepia.

CLYM ▲ETON ▲LQDA ▲TECX ▲URGN ▲

RTTNews·52dRead more ▾